Cephalon Drug Patent Portfolio
Cephalon owns 4 orange book drugs protected by 35 US patents Given below is the list of Cephalon's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8436190 | Bendamustine pharmaceutical compositions | 26 Apr, 2031 | Active |
| US8436190 | Bendamustine pharmaceutical compositions | 26 Oct, 2030 | Active |
| US8344006 | Liquid formulations of bendamustine | 23 Mar, 2030 | Active |
| US8445524 | Solid forms of bendamustine hydrochloride | 26 Sep, 2029 | Active |
| US8669279 | Solid forms of bendamustine hydrochloride | 26 Sep, 2029 | Active |
| US8883836 | Solid forms of bendamustine hydrochloride | 26 Sep, 2029 | Active |
| US9533955 | Solid forms of bendamustine hydrochloride | 26 Sep, 2029 | Active |
| US8344006 | Liquid formulations of bendamustine | 23 Sep, 2029 | Active |
| US8445524 | Solid forms of bendamustine hydrochloride | 26 Mar, 2029 | Active |
| US8669279 | Solid forms of bendamustine hydrochloride | 26 Mar, 2029 | Active |
| US8883836 | Solid forms of bendamustine hydrochloride | 26 Mar, 2029 | Active |
| US9533955 | Solid forms of bendamustine hydrochloride | 26 Mar, 2029 | Active |
| US7862832 | Generally linear effervescent oral fentanyl dosage form and methods of administering | 15 Jun, 2028 | Active |
| US7862833 | Effervescent oral opiate dosage forms and methods of administering opiates | 15 Jun, 2028 | Active |
| US8609863 | Bendamustine pharmaceutical compositions | 12 Jul, 2026 | Active |
| US8791270 | Bendamustine pharmaceutical compositions | 12 Jul, 2026 | Active |
| US8895756 | Bendamustine pharmaceutical compositions | 12 Jul, 2026 | Active |
| US8609863 | Bendamustine pharmaceutical compositions | 12 Jan, 2026 | Active |
| US8791270 | Bendamustine pharmaceutical compositions | 12 Jan, 2026 | Active |
| US8895756 | Bendamustine pharmaceutical compositions | 12 Jan, 2026 | Active |
| US8092832 | Generally linear effervescent oral fentanyl dosage form and methods of administering | 30 Dec, 2024 | Expired |
| US8119158 | Effervescent oral fentanyl dosage form and methods of administering fentanyl | 30 Dec, 2024 | Expired |
| US6200604 | Sublingual buccal effervescent | 26 Mar, 2019 | Expired |
| US6974590 | Sublingual buccal effervescent | 26 Mar, 2019 | Expired |
| US8728441 | Sublingual buccal effervescent | 26 Mar, 2019 | Expired |
| US8753611 | Sublingual buccal effervescent | 26 Mar, 2019 | Expired |
| US8765100 | Transmucosal effervescent | 26 Mar, 2019 | Expired |
| US6723351 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol | 10 Nov, 2018 | Expired |
| US6855339 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol | 10 Nov, 2018 | Expired |
| US6861076 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol | 10 Nov, 2018 | Expired |
| US6884439 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol | 10 Nov, 2018 | Expired |
| US6982096 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol | 10 Nov, 2018 | Expired |
| US8273379 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol | 10 Nov, 2018 | Expired |
| US5958951 | Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride | 10 Jun, 2017 | Expired |
| US5866590 | Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation | 29 Apr, 2016 | Expired |
Latest Legal Activities on Cephalon's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cephalon.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2024 | US9533955 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jun, 2024 | US8344006 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Jul, 2023 | US8119158 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Jun, 2023 | US8092832 |
|
Expire Patent
Critical
| 08 Aug, 2022 | US8765100 |
|
Expire Patent
Critical
| 25 Jul, 2022 | US8753611 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Jun, 2022 | US7862832 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Jun, 2022 | US7862833 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 May, 2022 | US8895756 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 May, 2022 | US8883836 |
|
Maintenance Fee Reminder Mailed
Critical
| 21 Feb, 2022 | US8765100 |
|
Maintenance Fee Reminder Mailed
Critical
| 07 Feb, 2022 | US8753611 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Jun, 2021 | US8609863 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Nov, 2020 | US8445524 |
|
Expire Patent
Critical
| 02 Nov, 2020 | US8273379 |
Cephalon's Drug Patent Litigations
Cephalon's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 24, 2014, against patent number US8436190. The petitioner AGILA SPECIALTIES INC., challenged the validity of this patent, with Cephalon, Inc. as the respondent. Click below to track the latest information on how companies are challenging Cephalon's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8791270 | October, 2015 |
Terminated-Settled
(25 Aug, 2016)
| Cephalon, Inc. | Fresenius Kabi USA, LLC |
| US8895756 | November, 2015 |
Terminated-Settled
(25 Aug, 2016)
| Cephalon, Inc. | Fresenius Kabi USA, LLC |
| US8791270 | October, 2015 |
Terminated-Denied
(13 Apr, 2016)
| Cephalon, Inc. | AGILA SPECIALTIES INC. |
| US8436190 | December, 2014 |
Terminated-Settled
(16 Nov, 2015)
| Cephalon, Inc. | AGILA SPECIALTIES INC. |
Cephalon Drug Patents' Oppositions Filed in EPO
Cephalon drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 12, 2013, by Helm Ag. This opposition was filed on patent number EP06718390A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP06718390A | Jan, 2014 | Accord Healthcare | Revoked |
| EP06718390A | Jan, 2014 | Gallafent, Alison | Revoked |
| EP06718390A | Jan, 2014 | Taylor Wessing LLP | Revoked |
| EP06718390A | Jan, 2014 | Bendalis GmbH | Revoked |
| EP06718390A | Dec, 2013 | Actavis Group PTC ehf | Revoked |
| EP06718390A | Dec, 2013 | LEK Pharmaceuticals d.d. | Revoked |
| EP06718390A | Dec, 2013 | Helm AG | Revoked |
Cephalon's Family Patents
Cephalon Drug List
Given below is the complete list of Cephalon's drugs and the patents protecting them.
1. Fentora
Fentora is protected by 9 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7862832 | Generally linear effervescent oral fentanyl dosage form and methods of administering |
15 Jun, 2028
(3 years from now)
| Active |
| US7862833 | Effervescent oral opiate dosage forms and methods of administering opiates |
15 Jun, 2028
(3 years from now)
| Active |
| US8092832 | Generally linear effervescent oral fentanyl dosage form and methods of administering |
30 Dec, 2024
(4 months ago)
| Expired |
| US8119158 | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
30 Dec, 2024
(4 months ago)
| Expired |
| US6200604 | Sublingual buccal effervescent |
26 Mar, 2019
(6 years ago)
| Expired |
| US6974590 | Sublingual buccal effervescent |
26 Mar, 2019
(6 years ago)
| Expired |
| US8728441 | Sublingual buccal effervescent |
26 Mar, 2019
(6 years ago)
| Expired |
| US8753611 | Sublingual buccal effervescent |
26 Mar, 2019
(6 years ago)
| Expired |
| US8765100 | Transmucosal effervescent |
26 Mar, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fentora's drug page
2. Gabitril
Gabitril is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5958951 | Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride |
10 Jun, 2017
(7 years ago)
| Expired |
| US5866590 | Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation |
29 Apr, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gabitril's drug page
3. Treanda
Treanda is protected by 18 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8436190
(Pediatric)
| Bendamustine pharmaceutical compositions |
26 Apr, 2031
(5 years from now)
| Active |
| US8436190 | Bendamustine pharmaceutical compositions |
26 Oct, 2030
(5 years from now)
| Active |
| US8344006
(Pediatric)
| Liquid formulations of bendamustine |
23 Mar, 2030
(4 years from now)
| Active |
| US8445524
(Pediatric)
| Solid forms of bendamustine hydrochloride |
26 Sep, 2029
(4 years from now)
| Active |
| US8669279
(Pediatric)
| Solid forms of bendamustine hydrochloride |
26 Sep, 2029
(4 years from now)
| Active |
| US8883836
(Pediatric)
| Solid forms of bendamustine hydrochloride |
26 Sep, 2029
(4 years from now)
| Active |
| US9533955
(Pediatric)
| Solid forms of bendamustine hydrochloride |
26 Sep, 2029
(4 years from now)
| Active |
| US8344006 | Liquid formulations of bendamustine |
23 Sep, 2029
(4 years from now)
| Active |
| US8445524 | Solid forms of bendamustine hydrochloride |
26 Mar, 2029
(3 years from now)
| Active |
| US8669279 | Solid forms of bendamustine hydrochloride |
26 Mar, 2029
(3 years from now)
| Active |
| US8883836 | Solid forms of bendamustine hydrochloride |
26 Mar, 2029
(3 years from now)
| Active |
| US9533955 | Solid forms of bendamustine hydrochloride |
26 Mar, 2029
(3 years from now)
| Active |
| US8609863
(Pediatric)
| Bendamustine pharmaceutical compositions |
12 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8791270
(Pediatric)
| Bendamustine pharmaceutical compositions |
12 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8895756
(Pediatric)
| Bendamustine pharmaceutical compositions |
12 Jul, 2026
(1 year, 2 months from now)
| Active |
| US8609863 | Bendamustine pharmaceutical compositions |
12 Jan, 2026
(8 months from now)
| Active |
| US8791270 | Bendamustine pharmaceutical compositions |
12 Jan, 2026
(8 months from now)
| Active |
| US8895756 | Bendamustine pharmaceutical compositions |
12 Jan, 2026
(8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Treanda's drug page
4. Trisenox
Trisenox is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6723351 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
10 Nov, 2018
(6 years ago)
| Expired |
| US6855339 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
10 Nov, 2018
(6 years ago)
| Expired |
| US6861076 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
10 Nov, 2018
(6 years ago)
| Expired |
| US6884439 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
10 Nov, 2018
(6 years ago)
| Expired |
| US6982096 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
10 Nov, 2018
(6 years ago)
| Expired |
| US8273379 | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
10 Nov, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trisenox's drug page